Dated disclosed rounds · latest 2021-02-01
Later stage / growth
Evox Therapeutics
Exosome-based drug delivery
VerifiedSeries COxford
- Companies House
- 10076821
- GLEIF LEI
- Not matched
- Latest evidence
- 2021-02-01
- Evidence snapshot
- 2026-08-25
Exact award notices · latest No exact award match
2026-08-25T03:37:20.637Z
Jun 2026
Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.
Evidence timeline
5 dated observations
Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.
RegistryRecord observation Status observed: Active
Snapshot evidence only; this row does not claim the status changed on this date.
FundingSource fact Series C
£69.2M · 1 named investor
FundingSource fact Series B
£35.5M
RegistryRegistry fact Company incorporated
EVOX THERAPEUTICS LIMITED · company 10076821
FundingSource fact Series A
£10M · 1 named investor
Latest disclosed round
Series C
- Date
- 2021-02-01
- Amount
- GBP 69.2m
- Sector
- Biotech & techbio
- Companies House
- 10076821
- ONS region
- South East
Evidence status
Directory ready
- Identity
- Verified
- Match
- High — exact company number and aligned registered name
- Operating status
- active
- Data origins
- Core directory, Live Chris T D1
Capital network
2 linked investors
Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.
| Investor | Role | Date | Source | Match / state |
|---|---|---|---|---|
| Oxford Sciences Innovation | lead | 2016-01-01 | Evoxtherapeutics ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Redmile Group | lead | 2021-02-01 | Evoxtherapeutics ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Funding record
3 disclosed rounds
Open a dated round to move directly between the company, named investors and source publication.
| Date | Stage | Amount | Investors | Named sources |
|---|---|---|---|---|
| 2021-02-01 | Series C | £69.2M | Redmile Group | Evoxtherapeutics ↗ |
| 2018-09-01 | Series B | £35.5M | Not stated | Evoxtherapeutics ↗ |
| 2016-01-01 | Series A | £10M | Oxford Sciences Innovation | Evoxtherapeutics ↗ |
Companies House status and filing snapshot
EVOX THERAPEUTICS LIMITED
Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.
Registered record
- Status
- Active
- Company type
- Private Limited Company
- Country of origin
- United Kingdom
- Incorporated
- 2016-03-22
- Dissolved
- Not applicable
- Company number
- 10076821
Filing context
- Accounts category
- FULL
- Accounts made up to
- 2025-12-31
- Next accounts due
- 2027-09-30
- Confirmation made up to
- 2026-03-16
- Registry snapshot
- 2026-08-01
- Live check
- 2026-08-25T03:37:20.637Z
72110Research and experimental development on biotechnology
CompanyBeacon statutory projection
EVOX THERAPEUTICS LIMITED
UK Capital Intelligence owns the capital view on this page. CompanyBeacon owns the exact legal-entity, filing, control and public-record timeline for company number 10076821.
Latest retained status
active
- Checked
- 2026-08-25T03:37:20.637Z
- Recorded change
- No change timestamp retained
- Previous status
- active
- Fund associations
- 1 dated CompanyBeacon membership
Boundary
Verify the legal record
Fund association does not prove a current holding. Status change is a review signal, not investment performance or wrongdoing. Ownership and control are not copied into this public UKCI package.
Open CompanyBeacon record ↗Traceability
Source trail
Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.